Financials in USD. Standardized financial statements.
A compact view of how Harvard Bioscience, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $86.55M | $94.14M | $112.25M | $113.33M | $118.90M | $102.10M | $116.18M | $120.77M | $101.88M | $104.52M |
| Revenue Growth? | -8.1% | -16.1% | -1.0% | -4.7% | +16.5% | -12.1% | -3.8% | +18.5% | -2.5% | 0.0% |
| Cost of Revenue? | $40.67M | $39.37M | $46.18M | $52.52M | $51.25M | $44.06M | $51.85M | $57.59M | $54.28M | $56.11M |
| Gross Profit? | $45.88M | $54.77M | $66.07M | $60.82M | $67.65M | $58.04M | $64.32M | $63.18M | $47.60M | $48.41M |
| Gross Margin? | +53.0% | +58.2% | +58.9% | +53.7% | +56.9% | +56.8% | +55.4% | +52.3% | +46.7% | +46.3% |
| Operating Expenses? | $46.51M | $60.98M | $64.18M | $67.75M | $65.59M | $57.82M | $63.95M | $62.20M | $47.70M | $49.55M |
| Operating Income? | -$629,000 | -$6.21M | $1.89M | -$6.93M | $2.07M | $221,000 | $377,000 | $984,000 | -$101,000 | -$3.00M |
| EBITDA? | $5.32M | -$1.47M | $8.03M | $944,000 | $9.02M | $5.17M | $7.64M | $5.36M | -$101,000 | $1.80M |
| Income Before Tax | -$57.39M | -$11.66M | -$2.56M | -$9.18M | -$140,000 | -$7.29M | -$5.50M | -$8.52M | -$2.09M | -$3.08M |
| Income Tax Expense | -$686,000 | $740,000 | $859,000 | $337,000 | $148,000 | $518,000 | -$815,000 | -$3.68M | -$1.22M | $1.23M |
| Net Income? | -$56.70M | -$12.40M | -$3.42M | -$9.52M | -$288,000 | -$7.81M | -$4.69M | -$3.46M | -$865,000 | -$4.31M |
| EPS? | $-12.80 | $-2.80 | $-0.81 | $-2.30 | $-0.07 | $-2.00 | $-1.20 | $-0.97 | $-0.26 | $-1.30 |
| Diluted EPS? | $-12.80 | $-2.80 | $-0.81 | $-2.30 | $-0.07 | $-2.00 | $-1.20 | $-0.95 | $-0.25 | $-1.30 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality